Efficacy and safety of a first dose of whole‐cell pertussis vaccine vs a first dose of acellular pertussis vaccine
All‐cause serious adverse events · the promotion of growth and prevention of infections in infants less than six months of age
Efficacy and safety of a first dose of whole‐cell pertussis vaccine showed no clear difference in all‐cause serious adverse events compared with a first dose of acellular pertussis vaccine (moderate certainty).
1 finding from 1 review
- Whole‐cell pertussis vaccine in early infancy for the prevention of allergy in children 2021 · Cochrane Headline outcomes onlyRR 0.94 [0.78, 1.15]15 studies · 38072 participantsModerate